r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction.

r84-treated tumors had reduced MVD, VEGFR2 expression, and LVD as compared to control-treated tumors, and showed a trend towards increased pericyte-associated blood vessels.

also in 53,322 other papers

There was a trend towards a decrease in final pancreas weight at time of sacrifice in mcr84-treated animals as compared to control, although this decrease failed to reach statistical significance.

also in 6,035 other papers

Tumor burden, as assessed by final pancreas weight at sacrifice, was reduced in mcr84-treated animals as compared to control- and sunitinib-treated animals, although this trend failed to reach significance ( Figure S2C ).

also in 4,113 other papers